Apparently bad - and somewhat puzzling - early news from the Phase III trial with its personalized kidney cancer vaccine sent Antigenics Inc.’s stock reeling. The company has suspended part two of the study while analyzing top-line data from the first part, and planning more changes at the firm to reduce the burn rate. (BioWorld Today)

A week after finishing pivotal trials with its nausea drug, Hana Biosciences Inc. signed a letter of intent to double its pipeline of compounds by licensing worldwide rights to three targeted chemotherapeutics from Inex Pharmaceuticals Corp. in a stock-and-cash deal worth up to $42 million. (BioWorld Today)

No Abstract West Coast EditorCerus Corp. priced its public offering of 4.5 million shares at $8.75 per share for proceeds of about $39.4 million, and the company expects to net about $36.9 million after expenses, or $42.5 million if the underwriters exercise their option to buy 675,000 more shares.The company’s shares (NASDAQ:CERS) closed Thursday at $8.75, down 46 cents.